MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
2142.HK stock logo

2142.HK

HBM Holdings Limited

$13.13
-0.34
 (-2.52%)
Exchange:  HKSE
Market Cap:  10.971B
Shares Outstanding:  175.804M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Jingsong Wang
Full Time Employees:  183
Address: 
Tower A, 12th Floor
Shanghai
200032
CN
Website:  https://www.harbourbiomed.com
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People’s Republic of China.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202220232024
Revenue40,65989,50238,100
Gross Profit40,52987,46833,614
EBITDA-130,21231,185-2,077
Operating Income-121,88821,827-3,695
Net Income-137,26822,7972,778

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202220232024
Total Assets232,123228,480215,014
Total Liabilities139,622108,85190,962
Total Stockholders Equity92,826119,988124,447
Total Debt90,92966,01261,339
Cash and Cash Equivalents171,705140,324166,821

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202220232024
Operating Cash Flow-99,964-19,12230,676
Capital Expenditure-18,438-2,480-235
Free Cash Flow-118,402-21,60230,441
Net Income-137,02022,6823,739
Net Change in Cash105,401-21,38126,497

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)231,249.676Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)247,845.833Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)239,547.755Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-134,138.450Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-125,156.323Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-129,647.387Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)293,872.072Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)314,962.467Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)304,417.270Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)0Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
24.52
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
40.17
?Enterprise Value
 (TTM)
: 
1.339B  ?EV/FCF
 (TTM)
: 
-233.06
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.18  ?ROIC
 (TTM)
: 
0.08
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.23
?P/B
 (TTM)
: 
5.29  ?Current Ratio
 (TTM)
: 
6.05

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
187.57Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate HK Intrinsic Value

Common questions about 2142.HK valuation

Is HBM Holdings Limited (2142.HK) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for HBM Holdings Limited (2142.HK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 2142.HK a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 2142.HK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 2142.HK’s P/E ratio?

You can see 2142.HK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 2142.HK?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 2142.HK a good long-term investment?

Whether 2142.HK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

2142.HK

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.52
MARKETSnap

Trading Metrics:

Open: 13.47   Previous Close: 13.47
Day Low: 12.93   Day High: 13.47
Year Low: 7.52   Year High: 17.98
Price Avg 50: 12.93   Price Avg 200: 12.98
Volume: 3.053M   Average Volume: 3.491M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for HK

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read